Back to results
US 8,148,089 B2Granted
Alpha-synuclein kinase
AssigneeElan Pharma International Limited
InventorsJohn P. Anderson, Kelly Banducci, Guriqbal S. Basi, David Chereau, Tamie J. Chilcote, Normand L. Frigon, Jr., Jason Goldstein, Irene Griswold
Life of this patent
Estimating the term…
Abstract
The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.
Claims12
A method of identifying an agent that reduces alpha-synuclein phosphorylation in a mammalian cell comprising:
- a) providing a mammalian cell expressing alpha-synuclein and expressing PLK2;
- b) contacting the mammalian cell with a test agent;
- and
- c) measuring the level of phosphorylated alpha-synuclein in the mammalian cell, wherein a reduction in the level of phosphorylated alpha-synuclein in the mammalian cell relative to the level in a control cell not contacted with the test agent is indicative that the test agent reduces alpha-synuclein phosphorylation.
1 more element
A method of identifying an agent that reduces alpha-synuclein phosphorylation in a mammalian cell comprising:
- a) providing a mammalian cell expressing alpha-synuclein and expressing PLK2 and expressing synphilin;
- b) contacting the mammalian cell with a test agent;
- and
- c) measuring the level of phosphorylated alpha-synuclein in the mammalian cell, wherein a reduction in the level of phosphorylated alpha-synuclein in the mammalian cell relative to the level in a control cell not contacted with the test agent is indicative that the test agent reduces alpha-synuclein phosphorylation.
1 more element
Dependencies are inferred from the claim text.